GlassScriptPhysician profile
Juan M Romero
NPI 1447299631
$6,044.69
in general payments reported to CMS, 2019-2025
16 companies · $1,048 in 2025
The $1,048 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $59.60 · 2021: $282 · 2022: $726 · 2023: $2,715 · 2024: $830 · 2025: $1,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,380 · Consulting Fee: $2,115 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,379.55 |
| Consulting Fee | $2,115.00 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $2,919.35 | 2019-2025 | Susvimo, Vabysmo |
| Regeneron Healthcare Solutions, INC. | $1,268.54 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $352.27 | 2024-2025 | Syfovre |
| Abbvie INC. | $281.82 | 2022-2025 | Ozurdex |
| Coherus Oncology, INC. | $210.75 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $167.08 | 2024-2025 | Acthar |
| Bausch & Lomb Americas INC. | $150.00 | 2025 | Envista Mx60 Iol |
| Genzyme Corporation | $119.57 | 2024 | |
| Kala Pharmaceuticals, INC. | $119.32 | 2019 | |
| Alcon Vision LLC | $106.49 | 2022 | |
| Novartis Pharmaceuticals Corporation | $94.33 | 2019-2021 | |
| Allergan, INC. | $88.98 | 2019-2021 | |
| Eyepoint US, INC. | $48.25 | 2022-2023 | |
| Astellas Pharma US INC | $47.58 | 2023-2025 | Izervay |
| Sandoz INC. | $47.38 | 2024 | Cimerli |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $22.98 | 2025 | Iheezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Romero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.